The authors have developed a cell-based high-throughput screening (HTS)-compatible assay to measure EGFR dimerization using the InteraX TM enzyme complementation technology of Applied Biosystems. The cells contain 2 chimeric proteins with complementing deletion mutants of the beta galactosidase enzyme, each fused to the extracellular and transmembrane part of EGFR. On binding of EGF, EGF receptor dimerizes and an active beta galactosidase is built. The authors used this homogeneous 384-well assay to screen about 20,000 diverse compounds. From 2 independent primary screen runs 239 hits were identified. For run 1, a mean S/B ratio of 4.26 and a mean Z′ factor of 0.74 were obtained, for run 2 a mean S/B ratio of 3.88 and a mean Z′ factor of 0.71 were obtained. After hit confirmation, repeated 4 times, 112 hits remained with a confirmation rate of 48.9%. Thirty of the 112 could be identified as cytotoxic. Fifty-one of the remaining 82 compounds could be shown to be inhibitors of the beta galactosidase enzyme itself. In summary, 31 compounds remained as potential EGFR dimerization or EGF stimulation inhibitors. The authors conclude that the InteraX TM system technology is HTS capable and can detect small molecule inhibitors capable of inhibiting protein-protein interactions. (Journal of Biomolecular Screening 2005:485-494) 
INTRODUCTION
A N INCREASING NUMBER of biological processes and diseaserelevant pathways are mediated through protein-protein interactions. The study of these interactions promises to lead to potentially novel intervention opportunities and the promise of new therapeutics. For drug discovery, in particular for high-throughput screening (HTS) applications, robust and reliable methods for monitoring such interactions are required. In the solution phase, many techniques are established for the labeling of isolated proteins and for measuring their interaction with other potential partner proteins. Many potential instances of protein-protein interactions take place preferentially in a cellular environment where tools and technologies to study these processes for drug discovery purposes are less commonly available. In this article, we present the results of an evaluation in an HTS environment of the InteraX™ system technology by Applied Biosystems. This technology uses the principle of enzyme complementation [1] [2] [3] [4] [5] [6] [7] [8] to generate a detectable activity signal. The technology is more fully de-scribed elsewhere 1, 2 and has been previously used, for example, to study G protein-coupled receptor activation and to identify potential inhibitors for receptor activation. 2 Briefly, the protein partners of interest are coexpressed as fusion proteins, each with 1 portion of a reporter enzyme, in this example, beta galactosidase. The individual reporter enzyme portions are in themselves enzymatically inactive, but when through the enforced interaction of their fusion partners they are brought together, enzymatic activity is generated. Thus, the degree of enzyme fragment complementation acts as an in situ monitor for the degree of protein-protein interaction. In a typical drug discovery application, the complemented activity can be reduced by the action of an inhibitor molecule against the protein partner-partner interaction.
In the present evaluation, the protein interaction of interest was the dimerization of the EGF receptor. The construction of the cell line has been previously described. 1, 4 Within the cell membrane are expressed 2 fusion proteins, each based on the fusion of the extracellular and membrane-spanning domains of EGFR with a fragment of beta galactosidase (Fig. 1 ). The study presented here describes the method development, testing, and evaluation of a random set of compounds drawn from the collection of Boehringer Ingelheim. In this way, the application of the InteraX™ system technology for drug discovery has been examined in a realistic screening scenario.
MATERIALS AND METHODS

Materials
White 384-well plates were purchased from Nunc (Nunc, Germany). Heat-inactivated fetal bovine serum (FBS) was obtained from Hyclone. Streptomycin, penicillin, geneticin, hygromycin B, L-glutamine, sodium pyruvate, bovine serum albumine fraction V, phenol red-free DMEM, and DMEM were purchased from Invitrogen (Invitrogen, Germany). The monoclonal antibody against EGF receptor (Ab-3, clone 255) 1, 4 was obtained from Oncogene, and human recombinant EGF was purchased from Upstate Biotechnology. Gal-Screen ® Reagent was obtained from Applied Biosystems; cell culture flasks were obtained from Nunc. All other chemicals were purchased from Sigma and were of the highest purity available.
Cell culture
The generation of the C2C12 cell line stably transfected with the EGF receptor-β-gal fusion proteins has been described elsewhere. 1, 4 These cells were a generous gift from Applied Biosystems. Cell culture was started using cells from passage No. 4. The cells were maintained under 10% CO 2 , 37°C, and 95% humidity and used regular growth medium (DMEM, 20% FBS, 0.1 mg/ml streptomycin, 100 IU/ml penicillin, 0.5 mg/ml G418, and 0.5 mg/ml hygromycin B). To grow the cells in plates, microplate growth medium was used (DMEM phenol red-free, 20% FBS, 0.1 mg/ml streptomycin, 100 IU/ml penicillin, 0.5 mg/ml G418, 0.5 mg/ml hygromycin B, 0.3 mg/ml L-glutamine, and 0.11 mg/ml sodium pyruvate). For performing the actual assay, the following assay medium was used: DMEM phenol red-free and 0.1% bovine serum albumin (BSA).
For all assays, 175 cm 2 cell culture flasks containing cells grown to 80% to 90% of confluency were used to prepare the cell suspension. Cells were washed once with PBS before adding 2 ml of Trypsin/EDTA to each cell culture flask. After 2 to 3 min of incubation, regular growth medium was added, and the cells were transferred to a 50-ml tube and centrifuged at 800 rpm for 5 min. Supernatant was aspirated, and the cells were suspended in microplate growth medium.
384-well plate assay protocol
A cell suspension was generated with a density of 1 to 2 × 10 5 cells/ml. The cells were seeded with a density of 5000 cells/well in a volume of 25 µl. The seeded plates were incubated for approximately 24 hours before performing the assay. On the day of assay, optimal S/N ratios were achieved with cells showing a 90% to 95% confluency. Culture medium was removed from the plates, and 20 µl/well of assay medium was added, followed by the addition of 5 µl/well of compounds prepared in assay medium (final DMSO concentration of 0.5%). After an incubation time of 5 min, 5 µl/ well of recombinant EGF prepared in assay medium (final concen-tration of 80 ng/ml) was added. After an incubation time of 60 min at 37°C and 10% CO 2 , 30 µl/well of Gal-Screen ® Reagent was added, and the plates were incubated at room temperature (RT) for 60 min, followed by the detection of the luminescence signal using a TopCount reader from Packard (1 s/well). Each plate contained wells with high values (cells + EGF), low values (cells without EGF), and control values (cells + EGF + inhibiting Ab clone 255).
Compound screening
HTS compound screening was performed using a set of 19,776 different compounds. These compounds were selected to be chemically diverse representatives of the Boehringer Ingelheim compound collection. The compounds used for screening were distributed over sixty-one 384-well plates. Rows 23 and 24 in each plate were empty and were used to fill in high, low, and control values. The compounds were presented as 5 mg/ml stocks and on the day of the assay diluted to give a final concentration in the test wells of 5 µg/ml. The final DMSO concentration achieved was 0.5%.
The screening was performed using 384-well plates with the assay protocol described above. The 19,776 compounds were screened 2 times on 2 different days. Cells of passage numbers 12 and 13 were used for these campaigns.
Hit confirmation screening
The compounds obtained in the primary screening campaign as hits were formatted as one 384-well plate with a compound concentration of 5 mg/ml in 100% DMSO. The hit confirmation was repeated 4 times using the 384-well assay protocol described above.
Cytotoxicity assay
To identify cytotoxic compounds within the set of hit compounds, a cytotoxicity assay was established. 5000 cells/well in a 384-well plate were used. The cells were plated out directly before use. After a 2-h incubation time, compounds were added, and the plates were incubated at 37°C and 10% CO 2 for 24 h. After this incubation time, the medium was aspirated and 20 µl DMEM medium without phenol red containing 5% of Alamar Blue™ Reagent was added, followed by an incubation time of 1 h at RT. After this time, the plates were read using a Farcyte reader (Amersham Bioscience Limited) and using the following filter set: excitation 544 nm, emission 595 nm.
Beta galactosidase assay
For the identification of direct beta galactosidase inhibitors within the set of hit compounds, a 384-well plate beta galactosidase assay was established. A recombinant beta galactosidase enzyme (Sigma G-5635) stock solution was prepared by reconstituting 1000 U/ml of beta galactosidase in buffer containing 1 M sodium phosphate (pH 7.0) and 0.1% of BSA. On the day of assay, this stock solution was diluted 1:750,000 using phenol red-free DMEM containing 0.1% of BSA. Of this dilution, 25 µl was pipetted into each well of a 384-well plate (Packard Optiplate) and 5 µl of the compound (final concentration 5 µg/ml) was added to each well. This results in a final dilution of the beta galactosidase enzyme of 1:900,000. After an incubation time of 1 h at 37°C, 30 µl of the beta galactosidase detection reagent was added followed by another 1-h incubation at RT. After this period, the plate was measured using a TopCount ® Reader (Perkin Elmer Limited).
Data analysis
Z′ determination was used to assess the quality of the assays established here. 9 The Z′ factor reflects the variation of data and the dynamic range of an assay signal. Z′ factor was calculated by using the following equation:
where SD = standardard deviation and x = mean value. The calculation of the percentage control values for the compounds tested was carried out using the following equation:
100.
The data were fitted using GraphPad Prism ® .
RESULTS
Assay development in 384-well plates
The aim of this study was to develop a robust 384-well EGF receptor beta galactosidase enzyme complementation assay compatible with HTS. To achieve this, several different parameters were optimized not only based on quality and stability issues but also based on speed and ease of assay performance. The general functionality of the assay has been previously described. 1, 4 Here, we focused on the development of the assay under clear HTS conditions. Therefore, we compared the following parameters: cells cultured 24 h before performing the assay versus cells used directly for testing, EGF concentration dependency of the signal window, cell number dependency of the assay signal, aspiration versus nonaspiration of the assay medium before adding Gal-Screen ® Reagent, DMSO dependency of the assay signal, stability of the assay signal after adding Gal-Screen ® Reagent, and comparison of different counting times for each well. Figure 2 summarizes the results obtained by plating out the cells 2 h before the assay was performed. It further shows an EGF titration curve and the resulting EC50 values for different numbers of cells per well. It further compares the data obtained by aspirating the assay medium before adding the Gal-Screen ® Reagent with those obtained by not aspirating. The EC50s generated for EGF were in the range of 4 to 9.4 ng/ml depending on the cell number per well and the experiment itself. The results obtained were in the range reported in the literature. 1, 10, 11 The signal-tobackground (S/B) ratio was in the range of 5.0 to 6.4. Z′ factors were achieved between 0.69 and 0.89, with n = 4 for each concentration tested. We could not see a difference between the results of experiments comparing aspiration versus nonaspiration of the assay medium in advance of adding the Gal-Screen ® Reagent. Figure 3 shows experiments in which the cells were plated out 24 h before the assay was performed. It also contains an EGF titration curve and a cell number dependency of the assay signal. Furthermore, a comparison was made between aspiration and nonaspiration of the assay medium before adding Gal-Screen ® Reagent. The EC50s for EGF were in the range of 12.1 to 28.7 ng/ml depending on the experiment and on the cell number per well. The S/B ratio was in the range of 5.1 to 5.6 here, and the Z′ factors were between 0.55 and 0.93, with n = 4 for each concentration tested. We observed no difference in experiments comparing aspiration versus nonaspiration of the medium in advance of adding Gal-Screen ® Reagent.
Based on these results, it was decided to perform the subsequent assays by using cells incubated 24 h before performing the assay and to continue to work with either 5000 or 7500 cells per well of a 384-well plate.
To examine the influence of DMSO on the assay performance, concentration response curves for EGF were performed using either 5000 or 7500 cells per well and the following DMSO concentrations: 0%, 0.25%, 0.5%, 0.75%, and 1.0%. The results obtained InteraX™ System Technology in this experiment are summarized in Figure 4 . Using 5000 cells per well, EC50s for EGF were in the range of 10.5 to 18.6 ng/ml, S/ B ratio was in the range of 3.6 to 4.3, and Z′ values were between 0.5 and 0.8. Performing the assay with 7500 cells per well, EC50s for EGF were between 18.5 and 28.2 ng/ml, S/B ratios were between 3.9 and 4.7, and Z′ values were in the range of 0.7 to 0.9. The variability of the EC50s for EGF in the presence of this range of DMSO concentrations was insignificant compared to day-to-day experimental variation. To further confirm the results obtained using different DMSO concentrations and to determine the influence of incubation time with the Gal-Screen ® Reagent, a similar set of experiments as described in the paragraph above was performed in which the incubation times with the Gal-Screen ® Reagent were varied between 1 h and 2 h, 30 min. The results are summarized in Figure 5 . There was no significant difference between 1-h incubation time and 2-h, 30min incubation time in the data obtained. Therefore, the shorter incubation time for running the experiment was chosen. Figure 6 shows the data obtained from varying the counting time for each well between 1 s/well and 4 s/well. There was no sig-nificant difference demonstrated within the set of experiments. Therefore, 1 s/well was chosen to be sufficient as detection time.
Performing an HTS campaign, it is essential to know if one can prepare reagents in advance or if they have to be prepared just before use. We compared working stocks of EGF preprepared and stored at -20°C (here called preprepared EGF) with freshly prepared EGF. As seen in Figure 7 , there was no clear difference between the results. Because of this, it was decided to prepare EGF in advance. 
InteraX™ System Technology
FIG. 5.
Effect of incubation times with Gal-Screen ® Reagent (1 h and 2 h, 30 min) comparing the influence of DMSO. The cells were plated out 24 h before assay start. Five thousand cells per well were used. EC50s for EGF are indicated in ng/ml. The tables below the graphs summarize the signal-to-background (S/B) ratio and Z′ factors achieved.
As a final optimization step, we tested 2 EGF concentrations and performed an antibody titration employing the antibody Ab-3 clone 255, an inhibiting antibody for EGFR dimerization, to validate the assay system. As shown in Figure 7 , the antibody inhibited the dimerization event in a dose-dependent manner. Comparing experiments using 5000 cells or 7500 cells per well, it was observed that the effect of the antibody was weaker with 7500 cells per well. Using the antibody as an assay control, we decided to work with an EGF concentration of 80 ng/ml, an antibody concentration of 1000 ng/ml, and 5000 cells/well.
Screening results
After finalizing the assay protocol, the primary screen was performed twice over with 19,776 different compounds. As shown in Figure 8 , using a selection criterion of 59% of control for each run, we obtained in the first run 65 hits ( Fig. 8A ) and in the second run 140 hits (Fig. 8B ). Following our normal statistical practice, we applied a cutoff criterion of 59% of control plus 1× standard deviation to the data from both runs together and identified 239 hits (Fig.  8C ). This represents a hit rate of 1.2%.
For logistical reasons, only 229 of the 239 hits could be taken into hit confirmation studies. The hit confirmation was performed 4 times, and the results are summarized in Table 1 . From the composite of all 4 runs, 112 confirmed hits were identified, representing a confirmation rate of 48.9%.
To exclude potential cytotoxic compounds, the same 229 compounds were also tested in a cytotoxicity assay. The test was performed twice, and the same high cutoff limit was chosen as was used in the primary screening campaign. Forty-four compounds were thereby identified as cytotoxic ( Table 2 ). Of these 44 compounds, 30 were present in the confirmed hit set of 112 com-pounds. Thus, after performing the cytotoxicity assay, 82 compounds remained.
In a next filter step, a beta galactosidase assay was employed to filter out potential inhibitors of the beta galactosidase enzyme itself. The same 229 compounds were used for running this assay 2 times. Sixty compounds could be identified generating a positive signal using the cutoff criteria of ≤73.4% (Table 3 ). Fifty-one of these 60 compounds were present in the set of 82 compounds remaining after the cytotoxicity assay.
After performing all these tests, 31 compounds remained, which showed confirmed activity in the dimerization assay and which were not positives in the cytotoxicity and the beta galactosidase assay under the conditions and criteria chosen here.
Summarizing the results obtained during the 2 independent primary screening runs, in the first run, a mean S/B value of 4.3 for the 61 plates tested and a mean Z′ factor of 0.74 were obtained, whereas in the second run, a mean S/B value of 3.9 and a mean Z′ value of 0.71 were obtained. During the development of the 384- FIG. 7 . Dose response of signal in response to inhibiting Ab-3 clone 255. Comparison of preprepared EGF versus freshly prepared EGF for 5000 and 7500 cells/well. Cells were plated out 24 h before assay start.
Concentrations of EGF used are indicated. EC50s for the Ab are indicated in ng/ml. The tables below the graphs summarize the signal-to-background (S/B) ratio and Z′ factors achieved.
well assay protocol and during the compound screens, the cell line was kept permanently in culture, and no change in behavior over 14 passages (7 weeks) was observed. Table 4 summarizes the results obtained for each of the remaining 31 compounds during the 2 primary screening runs and the 4 independent hit confirmation runs. The data underline the reproducibility of the obtained results.
DISCUSSION
Earlier publications have demonstrated the successful implementation of a beta galactosidase enzyme complementation assay employing mammalian cells expressing EGF receptor. 1, 2, 4 In our present study, we wished to demonstrate a robust cellular screen- ing assay measuring the EGF receptor dimerization after EGF stimulation in a 384-well format. The assay was used to perform a medium-throughput screening campaign using a set of about 20,000 compounds, which were representatives of the chemical diversity within the Boehringer-Ingelheim compound collection. During this HTS campaign, we wanted to study the reproducibility and the quality of this cell-based assay and we wanted to evaluate the complementation technology itself by employing the EGF receptor model. During assay development, we focused on establishing a screening assay that minimized reagent consumption including the amount of cells necessary for screening. We further focused on an optimized workflow to save time.
Because there was no difference between using cells directly or incubating them 24 h before the screening campaign, we decided to work with a 24-h preincubation. This gave us the possibility to prepare the cells a day in advance and to be able to start screening earlier the next day. The signal we obtained using 5000 cells was sufficient to fit our assay quality parameters. The EGF concentration chosen for stimulation was 80 ng/ml. This gave us the chance not to work with a maximum stimulated system and to be still in the linear range of the EGF stimulation curve. We also optimized the incubation times and the reading times of the assay consistent with maintaining good assay parameters. There was no significant difference in the assay-to-assay or day-to-day variation for the compound screen with respect to the DMSO concentration, which was tested in the range between 0% and 1%. A concentration of 0.5% DMSO was finally used. Because no small-molecularweight compound able to block EGF stimulation is known, we worked with the antibody Ab-3 clone 255 as inhibition control. 1, 4 A concentration of 1000 ng/ml showed complete inhibition of EGF stimulation. The IC50s for EGF stimulation using the final assay protocol (24-h incubation) were similar to values reported in the literature. 1, 10, 11 The EC50s for EGF with cells used 2 h after being plated out were lower than the EC50 for EGF for cells plated out 24 h before starting the assay. This might reflect cell growth over the 24-h incubation period. The S/B ratios and Z′ factors appeared better than in other studies using this new technology. 1 One aim of our study was to demonstrate whether compounds showing potential as protein dimerization inhibitors could be identified within the Boehringer-Ingelheim compound pool using this technology approach. Therefore, we screened approximately 20,000 compounds selected to contain chemically diverse compounds from the Boehringer-Ingelheim pool 2 times using the es- tablished assay protocol. Analyzing the data of these 2 runs and using a cutoff limit of 73.4% (cutoff limit 59% plus 1× standard deviation), we obtained a standard deviation of 14.44% and 239 hits, representing a hit rate of 1.2%. We believe that for a 384-well cell-based assay format with 4 pipetting steps, a standard deviation of 14.44% is acceptable. Analyzing the 2 primary screening runs separately, we obtained for run 1 a mean S/B ratio of 4.26 and a mean Z′ value of 0.74 for the 61 plates tested. For run 2, we obtained a mean S/B ratio of 3.88 and a mean Z′ value of 0.71.
For a hit confirmation of the primary screening hits, 229 compounds were tested 4 times. As shown in Figure 8 , the S/B ratio and Z′ factors showed the same quality as in the primary screening campaign. Employing the same hit criteria (cutoff at 73.4%), the number of confirmed hits varied between 105 and 121 in the 4 independent runs. As a mean value, we ended up with 112 confirmed hits, representing a confirmation rate of 48.9%. After filtering out potential cytotoxic compounds and potential inhibitors of the beta galactosidase enzyme, 31 compounds remained. The data for these compounds are summarized in Table 4 . Each compound was measured 6 times: 2 times in the primary screening campaign and 4 times for hit confirmation. Several of these compounds show reasonable inhibition behavior in this system (4 below 20% control, 7 below 40% control, 11 below 50% control). Interestingly, the molecular weight of these hits lies in the range between 300 and 600, which could indicate suitability for further target-related investigation.
However, it cannot be excluded that some of the compounds have other modes of inhibition that we were not able to distinguish. Using this technology, we cannot distinguish between compounds that are direct dimerization inhibitors or compounds that bind to EGF itself. The technology itself does not further explain the binding mode or the binding site of potential inhibitors. It cannot be ruled out that the compounds identified here as positive hits could have a mode of action other than as dimerization inhibitors. Various hydrophobic compounds such as cholesterol, bile salts, and ionic surfactants have been previously shown to bind to and to change the composition of cellular membranes, causing changes in binding kinetics and related cellular consequences. 12, 13 Compounds acting through further nonspecific modes might also be identified.
Beyond testing the compounds directly for overt nonspecific effects, it might be helpful to check for selectivity on other protein targets or in other cell lines containing other beta galactosidase fusion proteins.
We have shown in our study that we were able to employ the InteraX™ EGF receptor cell line to establish a robust HTS-compatible screening assay that can provide reproducible high-quality data. We further identified 31 compounds that were not acting through nonspecific toxicity or beta galactosidase enzyme inhibition mechanisms and that had a molecular weight (in the range of 300-600) still small enough to act as potential small molecule dimerization inhibitors. Therefore, our studies underline the functionality of such a technology in HTS drug discovery applications.
The InteraX™ system technology represents a new methodology to study protein-protein interactions in living cells using standard HTS equipment and standard readers and provides the chance to identify new drug candidates acting on novel sites of action.
